*Division of Medical Oncology

‡Department of Surgery

§Department of Radiation Oncology, University of Washington

†Clinical Research Division, Fred Hutchinson Cancer Center

∥Medical Oncology, Providence-Swedish Cancer Institute, Seattle, WA

This work is supported in part by support to the Sarcoma Oncology Program of the University of Washington from Curt and Elizabeth Anderson and P30CA015704 (E.T.L., L.D.C., M.J.W.) and through the Paul G. Allen Research Center at Swedish Cancer Institute (K.G.P.). L.D.C. was supported in part by the Curt and Elizabeth Anderson Endowed Professorship in Sarcoma Research, and by funding from Steve and Jane Urner.

B.C. generated and analyzed the data and contributed to the primary draft writing. M.J.W. conceptualized the project, analyzed the data, and wrote the primary manuscript. All authors critically edited the original manuscript draft and read and approved the final manuscript.

E.T.L.—Clinical trial funding from BioAtla, Ayala, and SpringWorks. L.D.C.—Clinical trial funding from Eli Lilly, AADi, BluePrint Medicine, Iterion, Gradalis, Philogen, Advenchen Laboratories, and CBA Pharma. Honoraria or has served on advisory boards for Daaichi Sankyo. M.J.W.—Clinical trial support from Deciphera, Adaptimmune, GSK, Athenex, Foghorn Therapeutics, Shaqsi, Presage Biosciences, Inhibrx, and Incyte. Consulting fees from Adaptimmune, Epizyme, Aadi, and Deciphera. H.M.L.—Research funding from Tolmar, EliLilly, GE Healthcare, Sanofi, and Zymeworks. Consulting for GE Healthcare, Novartis, Sanofi, and Eli Lilly. J.M.S.—Research funding from Celcuity, Genentech, Xencor, Pfizer, SeaGen, Merck, Carisma, and Lyell. Consultant/advisory boards: A2 Biotherapeutics, Volastra Therapeutics, GE Healthcare, Sensei Therapeutics, and GlaxoSmithKline. The remaining authors declare no conflicts of interest.

Correspondence: Michael J. Wagner, MD, 825 Eastlake Ave E, Seattle, WA 98109. E-mail: [email protected].

Supplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal's website, www.amjclinicaloncology.com.